Could Aduhelm Be Taken Off Market If CMS Proposal Stands? ‘Everything Is On The Table,’ Biogen Says

 
• By Brenda Sandburg
Aducanumab
Alzheimer's disease drug Aduhelm (aducanumab) faces new hurdle with CMS national coverage decision • Source: Alamy

More from Drug Pricing

More from Scrip